Business
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
BANGALORE, India, December 02, 2025--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
About this update from Dr. Reddy's Laboratories Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f862bd8970b572987dd6ac425cee5ee6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WcNCg79Hikbvtm434GD12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f862bd8970b572987dd6ac425cee5ee6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4T5ycEHJvZ2H4BvW7FmPlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f862bd8970b572987dd6ac425cee5ee6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BANGALORE, India, December 02, 2025--(BUSINESS WIRE)--Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).","length":585,"tagName":"p"},{"type":"text","content":""We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112," said Dr. Murali Ramachandra, CEO. "AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become a best-in-class MALT1 inhibitor."","length":522,"tagName":"p"},{"type":"text","content":"Study Design and Key Findings","length":29,"tagName":"p"},{"type":"text","content":"The company is currently conducting a Phase 1 dose-escalation study evaluating AUR112 monotherapy in patients with relapsed/refractory lymphoid malignancies. Primary objectives include characterizing safety and identifying dose-limiting toxicities and secondary objectives include pharmacokinetics, pharmacodynamics, object...